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Background: There is wide variation in the techniques deployed to diagnose tuberculosis in the
UK, with little agreement on which tools or strategies are cost effective. This analysis there-
fore comprehensively evaluated the cost effectiveness of currently available diagnostic strat-
egies for routine diagnosis of TB in the NHS.
Methods: The analysis compared strategies consisting of Nucleic Acid Amplification Techniques,
culture and microscopy. A decision tree was used to estimate costs and Quality-Adjusted Life
Years (QALYs) from a UK health service perspective. The sensitivity and specificity of each test
determined the true and false positive and negative results in patients suspected of having active
tuberculosis. These results led to either early, correct diagnosis or delayed diagnosis and the asso-
ciated costs and QALYs. The presence of active tuberculosis combined with the side effects of
treatment was associated with reduction in quality of life. Costs included were test costs, drug
costs and themanagement of tuberculosis. Drug costswere basedon genericUK list prices.Uncer-
tainty in the model was explored through probabilistic and deterministic sensitivity analyses.
Results/conclusions: The cost effective strategy at threshold of £20,000 per QALY was a strategy
using only sputum microscopy and culture routinely, meaning Nucleic Acid Amplification Tech-
niques are not cost effective at baseline. When the prevalence of tuberculosis was increased,
however, nucleic acid amplification became cost effective at the same threshold. Aside from
the prevalence, the results were shown to be robust. At low tuberculosis prevalence, Nucleic Acid
Amplification Techniques may not be cost effective but their potential in higher prevalence situ-
ations is considerable.
ª 2011 Elsevier Ltd. All rights reserved.0 3075 1397; fax: þ44 207 631 5097.
london.ac.uk (R. Hughes).
1 Elsevier Ltd. All rights reserved.
Figure 1 Branch of model showing the structure (Strategy 4).
1. TPe True Positive; FPe False Positive; TN e True Negative;
FN e False Negative.
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Tuberculosis (TB) remains a major worldwide health
problem and its incidence in the United Kingdom is
increasing. Most recent figures indicate that there were
around 9000 new cases in the United Kingdom in 2009.1
With no new antibiotics in the pipeline, making sure that
available drugs are used appropriately to reduce bacterial
loads as early as possible is essential for effective TB care
and infection control. This can, in part, be achieved
through early and accurate diagnosis.2 A missed or delayed
diagnosis of TB due to a false negative result can lead to
increased risk of infection and prolong a patient’s illness. A
false positive result can lead to unnecessary treatment and
toxicity or missed alternative diagnoses like Chronic
Obstructive Pulmonary Disease (COPD) or Lung Cancer,3
both of which carry heavy morbidity and costs.
While there is a great deal of variation in clinical prac-
tice, the most common diagnostic pathway includes clinical
history and examination, often followed by a chest X-ray
leading to a clinical suspicion of TB. Microbiological
confirmation of the disease is not always possible but is
important for guiding treatment and can usually be ach-
ieved.3 Traditional, microbiological tests do not, however,
provide swift results. Sputum smear microscopy (SSM) can
be done the same day but is not sensitive and can result in
many false negatives. Solid culture is very accurate and can
be used to test for drug sensitivity but can take 6e8 weeks,
and even on faster automated liquid cultures takes 2e3
weeks.4
Nucleic Acid Amplification Techniques (NAAT) are
polymerase chain reaction tests that amplify nucleic acid
sequences in the TB genome, allowing the identification of
TB. In contrast to SSM, NAAT theoretically only require
one bacterium in the sample to achieve a positive result.
NAAT can be done the same day alongside genetic probes
that, like culture, can be used to identify drug resistance;
an important advantage over SSM. The diagnostic accu-
racy of NAAT has been widely reported as being higher
than SSM4e6 but any consideration of their adoption has to
take into account the cost, which is relatively high
compared to traditional tests. The National Institute for
Health and Clinical Excellence (NICE) guidance on TB
recommends that NAAT should only be used in rare
circumstances,7 while a more recent UK based health
technology assessment recommends their routine use.4
However most of these recommendations have been
made on accuracy grounds and have not expressly dealt
with issues of cost. This analysis will therefore compre-
hensively evaluate the cost effectiveness of currently
available diagnostic strategies for routine diagnosis of TB
in the NHS.
Methods
A review of the economic literature in this area revealed
that there were no existing economic evaluations that
addressed the issue of the routine use of NAATs in the UK.
As this study aims to inform resource allocation policy, the
study is a cost utility analysis, taking the NHS and Personal
and Social Services (PSS) perspective.Structure
A decision tree was constructed using TreeAge Pro 2009
Suite (TreeAge Software Inc, Williamstown, MA, USA), to
compare the costs and effects of eleven strategies. An
exhaustive list of testing strategies was developed and then
reduced to a list of the most commonly used and those that
would have significant impact on practice or cost. The
three studies marked with an asterisk (*) are all 100%
accurate.
1. SSM followed by Culture when SSM positive
2. SSM followed by Culture when SSM negative
3. SSM followed by Culture every time*
4. SSM and NAAT, Culture when discrepancy between
results
5. SSM and NAAT when SSM positive, otherwise Culture
6. SSM and NAAT when SSM negative, otherwise Culture
7. NAAT followed by Culture in every situation*
8. NAAT only
9. NAAT and Culture when NAAT positive
10. NAAT and Culture when NAAT negative
11. SSM and NAAT followed by Culture every time*
The model structure can be seen in Fig. 1 (Strategy 4 is
used as an example). A False Positive result leads to
unnecessary treatment, exposing a patient to potential
unnecessary toxicity, higher costs and delay until an
alternate diagnosis is made. This delay is assumed to be
until patient follow-up shows that the treatment is not
working. This was set at 4 months as the date for a second
follow-up appointment recommended by World Health
Organisation (WHO) guidance.8 If a False Negative result, by
either an NAAT or SSM with no culture is recorded there is
a delay of 99 days until eventual correct diagnosis.9 This
leads to increased bacterial load, increased infective risk to
others, and a loss of quality of life from active TB. The costs
and outcomes of other diagnoses both for false negatives
and true negatives are not considered here as there are
Table 1 Test accuracy.
Test accuracy Base case Probabilistic data Source
Sensitivity of NAAT 0.85 Mean sample size: 296, SD399 Beta Distribution Dinnes et al.4
SSM þve 0.968
SSM ve 0.734
Specificity of NAAT 0.959
SSM þve 0.965
SSM ve 0.937
Sensitivity of SSM 0.68 Mean sample size: Steingart10
Specificity of SSM 0.97 1907, SD 4874 Beta Distribution
Sensitivity of culture 1 Reference standard
Specificity of culture 1 Reference standard
Sensitivity of NAAT to MDR 1 Assumption
Sensitivity of culture to MDR 1 Assumption
Specificity of NAAT to MDR 1 Assumption
Specificity of culture to MDR 1 Assumption
302 R. Hughes et al.many alternative diagnoses for similar symptoms, all
carrying different costs and QALYs.
Using either culture or NAATs, the resistance of certain
strains of TB to standard treatment regimens can be
measured. This cannot be done using SSM. The diagnostic
accuracy for multidrug resistant TB (MDR) was assumed to
be the same for culture and NAAT. The sensitivity and
specificity of NAAT and culture to MDR was assumed to be
100%. This reflects the high accuracy of line probe assays
and culture drug susceptibility testing.4Test accuracy
Three strategies are 100% accurate as they are strategies
that use culture routinely. Bacterial culture is considered
the gold standard test and is used to determine the sensi-
tivity and specificity of other tests. NAAT accuracy is in
some respects dependant on the SSM result. As such there
are two separate accuracies used in the model for NAAT: (1)
when no prior information is available and (2) when the
results of the NAAT are conditional on SSM status, as shown
in Table 1. While the results of some strategies that include
both SSM and NAAT will actually be seen simultaneously by
a health professional, they are considered sequential in the
model. This better reflects the SSM status dependant
accuracy of NAATs. The decision rule used in the model is:
treat presumptively based on any positive result prior to
receiving the culture results.4 When presumptive treatment
has begun and a negative culture result is recorded, as
culture takes some time to undertake, treatment is dis-
continued. The opposite is also true; when treatment has
not begun due to false negatives and a positive culture
result is recorded, treatment will begin.
The pre-test prevalence in this study is defined as the
prevalence given a clinical suspicion of TB at presentation
to a health professional; based on expert opinione, this was
assumed to be 20% (but this assumption was tested thor-
oughly in a sensitivity analysis). The sensitivity ande Dr Bernard Higgins, Consulting Respiratory Physician, Freeman
Hospital, Newcastle upon Tyne.specificity of each test is used to determine the rate of True
Positive, True Negative, False Positive and False Negative
results and can be seen in Table 1.
Model parameters
The inputs (accuracies, probabilities, etc.) used in the
model were based on systematic reviews of the literature,
selected by the New Diagnostics Working Group (NDWG) of
the WHO’s Stop TB Partnership; through the “Evidence-
Based Tuberculosis Diagnosis” portal.11 The majority of the
data on diagnostics came from a single UK health tech-
nology assessment from 2007.4 Sources of costs were
identified through the NICE TB Guideline7 and the NDWG
portal. Utility data was identified using the Cost Effec-
tiveness Analysis Registry.12 The model was extensively
reviewed to ensure internal and external validity.
Drug treatment for TB is for the most part highly
effective in the United Kingdom. The standard treatment
effectiveness was assumed to be 100% when administered
to patients without drug resistance based on a Cochrane
review of TB treatment programmes.13 In the United
Kingdom, TB has a low fatality rate and it is unclear how
many deaths per year can actually be attributed to TB.
Added to this is the fact that many deaths attributed to TB
never actually start treatment.1 Therefore, the model
assumes zero fatalities. When a patient enters the model,
whichever strategy is used, the longest time from entry to
cure in the model is under one year. The long term health
effects of TB were investigated through a thorough search
of the literature. However, no relevant data on the impact
that delayed diagnosis has on long term prognosis of TB
patients could be found. The time horizon was therefore
set at one year with no discounting of future costs and
utilities necessary. A list of the model parameters can be
found in Table 2.
Model outcomes
The primary effectiveness measure for this study was
Quality Adjusted Life Years (QALYs) and number of
Table 2 Model parameters.
Time to TB diagnosis Base case Probabilistic data Source
SSM (days) 1 Dinnes et al.4
NAAT (days) 1
Culture (Solid) (Days) 49 CI: 42e56
Lognormal
Time to MDR identification NAAT (days) 1
Time to MDR identification culture (days) 49 CI: 42e56
Lognormal
Delay until diagnosis of FN (years) 0.27 CI: 0.15e0.44
Lognormal
Paynter et al.9
Delay until identification of FP (Years) 0.33 World Health Organisation8
Treatment effects
Duration of Isoniazid (months) 6 NICE7
Duration of Rifampicin (months) 6
Duration of Ethambutol (months) 2
Duration of Pyrazinamide (months) 2
Mean duration treatment (years) 0.5 Gelband et al.13
Proportion of people who suffer toxicity 0.045 CI: 0.03e0.06
Beta
StopTB14
Proportion of people who suffer toxicity (MDR) 0.3 CI: 0.27e0.33
Beta
Nathanson et al.15
Treatment time before no longer infectious (days) 14 CI: 10e18
Lognormal
Freiden et al.16
Outpatient treatment
Follow-up frequency (full regimen) 3 World Health Organisation8
Follow-up frequency (stops at 4 months) 2
Proportion of TB cases that are MDR 0.014 A Z 53/b Z 4755
Beta
Health Protection Agency1
Utility weights
Utility (general population level) 0.86 SE: 0.004
Lognormal
Kind et al.17
Utility loss for active TB 0.39 SE: 0.014
lognormal
Tan et al.18
Utility loss for active TB (undergoing treatment) 0.1 Khan et al.19
Utility loss for toxicity without TB 0.16 Holland et al.20
Utility loss for toxicity with TB 0.25
Infectivity
Number of infections per year (SSM positive) 10 MaxeMin: 8e10
Triangular
Dowdy et al.21
Relative infectivity of SSM negative TB 0.2 CI: 0.16e0.32
Beta
Behr et al.22
Nucleic Acid Amplification Techniques for the diagnosis of tuberculosis 303secondary infections resulting from the delays caused by
false negatives and positives. Utilities were calculated for
TB and no TB, with and without treatment and
toxicity.18e20 Drug toxicity is considerably more likely in
MDR treatment than standard TB treatment due to the
intensity of the drug regimens.15
The level of infectiousness was defined by SSM status.
When a branch was SSM positive it was classed as having
high infectivity and when SSM negative, low infectivity (see
Table 2). Where there was no information about the smear
status it was predicted and the appropriate level of infec-
tivity assigned.
Costs
A complete list of the costs used in the model can be found in
Table 3. These costs were used to cost three scenarios:a patient completing a full treatment regimen, a patient
receiving unnecessary treatment due to a false positive and
a patient receiving treatment, while awaiting a definitive
culture result. It was assumed that any time treatment was
changed; this would require a hospital appointment. An
example of where treatment change would be necessary is if
a patient had a false positive and had to have treatment
changed after culture results confirmed the patient was
negative forTB. Follow-upappointments at 2, 4 and6months8
were also assumed to be necessary based on WHO guidance.
Outpatient costs were calculated for each scenario using
Department of Health Tariffs and SSM costs. If costs had to be
updated or converted from another currency, this was done
using Purchasing Power Parity (theCCEMGe EPPI-Centre Cost
Converter23 was used). The cost of MDR was taken from the
NICETBGuideline.7 For the probabilistic analysis, all costs use
a gamma distribution as it is bounded by 0.
Table 3 Costs.
Base case Probabilistic data Source
Test costs
Cost of NAAT and MDR identification £120.00 SE: 24 Dinnes et al.4
Cost of SSM test £1.56 SE: 0.68 Dowdy et al.21
Cost of culture and MDR identification £30.00 SE: 6 Dinnes et al.4
Drug costs
Cost of isoniazid treatment (£ per month) £21.00 SE: 5.35 BNF 5924
Cost of rifampicin (£ per month) £11.29 SE: 4.3
Cost of ethambutol (£ per month) £9.25 SE: 1.53
Cost of pyrazinamide (£ per month) £6.88 SE: 1.17 White et al.25
Outpatient costs
Cost of outpatient consultation: initial
or follow-up visits (£/visit)
£167 SE: 33 Department of Health26
Cost per MDR TB case £27,844 SE: 5569 White et al.25
f INMB is calculated using the following formula
DE  WTPDC > 0Z CE. This formula gives the cost effectiveness
of a given intervention/strategy, incorporating the willingness to
pay (WTP) threshold, in this case £20,000.
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Deterministic sensitivity analyses were carried out by
varying key parameters to explore certain aspects of
uncertainty in the model (Table 4). The parameters in the
model have also been made probabilistic. This means that
the model parameters, instead of it being fixed point esti-
mates, are fitted with distributions. Whenever the model is
run, a random value is sampled from the distribution and
used in the model. The model is then run 1000 times, giving
the average cost effectiveness. In this way, the uncertainty
around each data point is expressly considered in the model
and can be used to show the probability of a strategy being
cost effective at a given threshold.
Cost effectiveness threshold
In England, the threshold for cost effectiveness is an
Incremental Cost Effectiveness Ratio (ICER) of £20,000 per
QALY gained. This threshold is, however, not completely
rigid and there are situations where this can be exceeded. A
higher limit of £30,000 will therefore also be examined.
Results
In the breakdown of costs and outcomes in Table 5, it is
possible to see that the biggest contributor to the differ-
ence in costs between strategies is the cost of tests. It is
also clear that while strategies including NAAT may not be
cost effective under our base case analysis assumptions,
their routine use could be effective in the prevention of
infections (strategy 11). Achieving an early correct diag-
nosis will prevent further cost and quality of life loss due to
infection.
In the base case analysis, the cost effective strategy at
a threshold of £20,000 per QALY gained is Strategy 3: where
SSM is followed by culture in every situation. This means
that strategies including NAAT are not cost effective in the
base case (Fig. 2). When the options that are more
expensive and less effective (dominated) have been
excluded from the results, the incremental cost effective-
ness ratio for strategy 3 is £9748 per QALY gained. The nextnon-dominated option is strategy 11 with an incremental
cost effectiveness ratio of £64,723 per QALY, far above the
usual cost effectiveness threshold.Sensitivity analyses
A series of one-way sensitivity analyses were run to see if
the model results were sensitive to any of the parameters
where there was particular uncertainty.
The pre-test prevalence was based on expert opinion
and as such was not particularly robust. This figure was
varied between 0 and 100% in a threshold analysis. This
showed that there are three prevalence levels at which
different strategies become cost effective. Strategy 1 is
cost effective between 0% and 10%; strategy 3 becomes
cost effective between 10% and 46% [A] and strategy 6 is
cost effective above 46% [B]. This shows that at higher
prevalence NAAT strategies could well be cost effective for
routine use alongside SSM. Fig. 3 shows this with Incre-
mental Net Monetary Benefits (INMB)f. INMBs are calcula-
tions that expressly include the cost effectiveness
threshold meaning that the higher the INMB, the more cost
effective the strategy at that threshold. When the INMBs
are compared to the lowest cost strategy (Strategy 1) we
can see the points at which each strategy becomes cost
effective, this happens when the strategy has the highest
INMB.
In general the deterministic sensitivity analysis results,
which all used the base case prevalence of 20%, were fairly
robust and strategy 3 was cost effective throughout. In only
two situations, the most cost effective strategy did change.
When the time to diagnosis of an FN is decreased to the
short time of 10.4 weeks strategy 1, as the lowest cost
option, becomes the optimal choice. When the costs of
NAAT are reduced to £42.66, strategy 6 becomes cost
effective. At any other price above that, strategy 3 remains
cost effective.
Table 4 Parameters for deterministic Sensitivity analyses.
Parameter Base case Range Source
Sensitivity of NAATs on SSM
negative samples
0.734 0.66e0.76 Dinnes et al.4
Sensitivity SSM 0.68 0.65e0.748 Steingart et al.10
Time to diagnosis (yrs) 0.13 0.11e0.15 Dinnes et al.4
Length of delay FN (yrs) 0.27 0.15e0.44 Paynter et al.9
Length of delay FP (yrs) 0.33 0.16e0.50 World Health Organisation8
Proportion of MDR 0.015 0.0e0.05 Dinnes et al.4
Cost of NAATs (£) 120 42.61e170.43 Rajalahti et al.27
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shows that as the willingness to pay threshold increases,
so does the probability that strategy 3 is cost effective. At
the £20,000 threshold, there is a 90% probability that
Strategy 3 is cost effective. If the cost effectiveness
threshold is increased to £30,000 or £40,000 per QALY,
Strategy 3 remains the cost effective option.Discussion
The results presented here would suggest that strategies
including NAATs are not cost effective for the diagnosis of
TB in general circumstances. It also suggests that the
strategy most closely approximating current usual care,
Strategy 3, is appropriate. From the sensitivity analysis on
prevalence, we can see that when there is a high risk of TB,
a full diagnostic work-up with SSM, NAAT and Culture is
preferable. This suggests that due to NAAT’s higher sensi-
tivity, they are best used when the pre-test prevalence of
TB is high and therefore it may be more useful in targeted
populations where a diagnosis of TB is more likely. Gener-
ally the sensitivity analyses suggest that the model is not
particularly sensitive to changes in its key variables. Quite
substantial changes in the cost of NAAT or time to recog-
nition of a false negative were required to change the base
case.
These results would tend to agree with the main body of
clinical4e6,28; and cost effectiveness27,29,30 literature on
the subject in recommending the use of NAAT as adjunct to,
but not replacing SSM and culture, at high TB prevalence.Table 5 Breakdown of costs and outcomes by increasing cost.
Costs/£
Strategy Test Costs Drug Costs Outpatient Costs MDR
1 6.36 46.69 119.23 61.3
3 31.56 46.69 119.23 61.3
2 26.76 48.81 123.56 61.3
5 46.78 46.64 118.87 61.3
6 110.02 50.50 127.68 61.3
9 126.10 47.26 115.93 61.3
8 120.00 49.99 121.51 61.3
4 125.27 50.45 127.32 61.3
7 150.00 47.26 115.93 61.3
10 143.91 49.99 121.51 61.3
11 151.56 50.38 127.18 61.3Rajalahti et al. 2004 assessed the cost effectiveness of
commercial NAAT for use in Finland and reached the
conclusion that NAAT is not cost effective at low prevalence
but could be at high prevalence. Another study by Dowdy
et al. 2003 assessed the cost effectiveness of the Roche
Amplicor MTB test on SSM positive patients. This study
concluded that the cost effectiveness of a particular NAAT
is sensitive to changes in prevalence in this population.29
We have confirmed these results in a UK population.
Various assumptions were made during the construction
of the model that simplified its structure. The assumption
that culture sensitivity and specificity was equal to 100%
was unavoidable as all the systematic reviews referred to
use culture as the reference standard. It has been sug-
gested, however, that culture’s accuracy is in fact not
100%4 and further analysis of the diagnostic accuracy of
culture compared against NAAT or SSM would be welcomed.
When a patient was subject to a false positive they were
simply treated until the false result was discovered. What
was not considered, however, was the impact of the
differential diagnosis. Various alternative diagnoses would
carry both cost and QALY loss implications. Consideration,
therefore, of the alternate diagnosis would strengthen the
model’s real life application. Another issue that is not
addressed is the financial implications of a false negative. Is
the person who is subject to a false negative tested or
treated for other conditions, and what are the costs asso-
ciated with this? This is perhaps an area for further
research.
It has been suggested that delays can worsen prognosis
of TB and that delays are prevalent in many health servicesOutcomes
Costs Total Costs Infections FPs FNs QALYs
8 233.65 0.10 0.02 0.06 0.842
8 258.85 0.08 0.02 0.06 0.844
8 260.51 0.08 0.02 0.06 0.844
8 273.67 0.08 0.02 0.06 0.844
8 349.57 0.07 0.07 0.02 0.845
8 350.66 0.13 0.03 0.03 0.844
8 352.88 0.13 0.03 0.03 0.844
8 364.41 0.07 0.07 0.02 0.845
8 374.56 0.13 0.03 0.03 0.846
8 376.79 0.13 0.03 0.03 0.846
8 390.50 0.06 0.07 0.02 0.846
Figure 2 Cost effectiveness plane. *Incremental Cost Effec-
tiveness Ratios; the cost effectiveness compared to the next
lowest cost option.
Figure 4 Cost effectiveness acceptability curve.
306 R. Hughes et al.around the world.9,31 There is, however, very little
evidence on the impact of delays on TB prognosis in the
United Kingdom or developed countries more generally.
Further research in this area should be encouraged and
would help to resolve certain unanswered questions over
the effects of early diagnosis on TB. Further to this, the
assumption of 100% efficacy and 100% adherence to treat-
ment is a limitation that biases the result away from NAAT.
The more often a patient has to make contact with the
health service, the greater the chance that any appoint-
ments made will be missed, diminishing adherence and
follow-up care. In this situation, the less follow-up required
the better, thus rewarding a more accurate initial
diagnosis.
One final limitation of the model is that it does not
include the cost and health implications of secondary
infections. However, approximate estimates of the number
of secondary infections are presented as a supplement to
the main model results (Table 5). The number of secondary
infections is lowest in the strategy that uses SSM, NAAT and
culture routinely. If secondary infections were incorporated
fully in to the model it could be that this strategy is optimal
even at quite low levels of prevalence. In order to do this
a more complex infectious disease model would be useful.Figure 3 Incremental Net Monetary Benefit compared with
Strategy 1 at a willingness to pay threshold of £20,000 per
QALY: highest INMB is the cost effective option. *At point [A]
Strategy 3 becomes cost effective and [B] strategy 6 is cost
effective.Another area for further research concerns the prevalence
of TB among those being tested. In general, TB is not
particularly prevalent in England although in certain areas
(London or Birmingham(1)) or certain populations (migrant
populations, homeless communities, drug users and people
with HIV7,32,33) it is highly prevalent. This raises the ques-
tion of at what prevalence would TB start to be considered
as a diagnosis.
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